SCHEMBL22423719

C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)COCCOCCOCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)[C@@H](C)O

nearest known ligand 0.56

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	RAMP3	O60896	9/20	0.56

▸	CALCR	P30988	9/20	0.56

▸	IL23R	Q5VWK5	1/20	0.53

▸	KDM1A	O60341	1/20	0.51

▸	MAOB	P27338	1/20	0.51

▸	KDM5A	P29375	1/20	0.51

▸	KDM1B	Q8NB78	1/20	0.51

▸	GLP1R	P43220	4/20	0.51

▸	GCGR	P47871	4/20	0.51

▸	TFPI	P10646	3/20	0.50

▸	PIN1	Q13526	1/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL26346380	0.85	GLP1R (0.60)	GLP1RGCGR
SCHEMBL24601727	0.85	GLP1R (0.60)	GLP1RGCGR
SCHEMBL22550671	0.82	RAMP3 (0.53)	RAMP3CALCRKDM1AMAOBKDM5A
SCHEMBL26209751	0.82	PLG (0.53)	RAMP3CALCRKDM1AMAOBKDM5A
SCHEMBL26209740	0.81	APLNR (0.50)	RAMP3CALCRKDM1AMAOBKDM5A
SCHEMBL12984646	0.80	RAMP3 (0.63)	RAMP3CALCRTFPIPIN1
SCHEMBL24601848	0.80	APLNR (0.52)	KDM1AMAOBKDM5AKDM1B
SCHEMBL12984102	0.80	RAMP3 (0.66)	RAMP3CALCRIL23RGLP1RGCGR
Biotin SCHEMBL6521802	0.78	GLP1R (0.59)	RAMP3CALCRGLP1RGCGRTFPI
SCHEMBL6176075	0.78	RAMP3 (0.52)	RAMP3CALCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20200291391-A1	CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF	REGENERON PHARMACEUTICALS, INC.	2020-09-17	—	—	US	disclosed
WO-2020186091-A1	CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF	INDI MOLECULAR, INC. (US)	2020-09-17	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20200291391-A1	CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF	CD74, HLA-DRB1, HLA-C	RAMP3 2393/4885CALCR 3060/4885IL23R 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.